scholarly journals Metyloprednizolon podawany doustnie lub dożylnie w leczeniu rzutu stwardnienia rozsianego – komentarz redakcyjny do artykułu Emmanuelle Le Page i wsp. pt.: Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial (Lancet 2015; 386: 974–981)

2016 ◽  
Vol 16 (2) ◽  
pp. 109-111
Author(s):  
Karol Jastrzębski ◽  
Keyword(s):  
Multiple Sclerosis ◽  
High Dose ◽  
Double Blind ◽  
High Dose Methylprednisolone ◽  
Randomised Controlled

scholarly journals Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial

The Lancet ◽  
2015 ◽  
Vol 386 (9997) ◽  
pp. 974-981 ◽  
Author(s):  
Emmanuelle Le Page ◽  
David Veillard ◽  
David A Laplaud ◽  
Stéphanie Hamonic ◽  
Rasha Wardi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
High Dose ◽  
Double Blind ◽  
High Dose Methylprednisolone ◽  
Randomised Controlled

scholarly journals Pulmonary function, computerized tomography features and six-minute walk test at three months in severe COVID-19 patients treated with intravenous pulsed methylprednisolone: a preliminary report

2021 ◽  
Author(s):  
Cristiano Van Zeller ◽  
Asad Anwar ◽  
Nordita Ramos-Bascon ◽  
Natalie Barnes ◽  
Brendan Madden
Keyword(s):  
Lung Function ◽  
Preliminary Report ◽  
Mean Value ◽  
High Dose ◽  
Walk Test ◽  
Six Minute Walk Test ◽  
High Dose Methylprednisolone ◽  
Randomised Controlled ◽  
Ct Finding ◽  
Minute Walk

COVID-19 ARDS has a high mortality and few therapeutic options. We present a preliminary report on our experience using high-dose pulsed methylprednisolone in COVID-19 ARDS and three-month outcomes. We performed a retrospective analysis of all patients treated with high-dose methylprednisolone for COVID-19 ARDS and three-month lung function, 6MWT, and CT findings. 15 patients were treated of which 10 survived to discharge. Reduced DLCO was the commonest abnormality in lung function tests and had the lowest mean value. Parenchymal bands were the commonest CT finding and 50% of patients had fibrosis at three-months. Mean 6MWD was 65.4% predicted and was abnormal in 62.5% of patients. In this cohort of patients with COVID-19 ARDS treated with high-dose methylprednisolone pulses, CT, lung function, and 6MWT abnormalities were unsurprisingly common at three months, although all 10 patients treated early in their disease course survived, a possible therapeutic effect. Further randomised controlled trials are needed to assess the benefits of this treatment.

Sign in / Sign up

Export Citation Format

Share Document